newsfilter
← Latest News
GlobeNewswire·

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel

SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today issued a statement